Evolutionary insights on the origin of human T-cell lymphoma/leukemia virus type I (HTLV-I) derived from sequence analysis of a new HTLV-I variant from Papua Ne
TY - JOUR. T1 - Hepatosplenic and other γδ T-cell lymphomas. AU - Vega, Francisco. AU - Medeiros, L. Jeffrey. AU - Gaulard, Philippe. PY - 2007/6/1. Y1 - 2007/6/1. N2 - The 2005 Society for Hematopathology/European Association for Haematopathology Workshop session 11 was dedicated to hepatosplenic T-cell lymphoma (HSTCL). HSTCL is a rare aggressive type of extranodal lymphoma characterized by hepatosplenomegaly, bone marrow involvement, and peripheral blood cytopenias. HSTCL exhibits a distinctive pattern of infiltration; tumor cells preferentially infiltrate the sinusoids of the splenic red pulp, liver, and bone marrow. The tumor cells have a nonactivated cytotoxic T-cell immunophenotype and frequently carry a recurrent cytogenetic abnormality, isochromosome 7q. Most cases express the γδ T-cell receptor, but cases can have an αβ phenotype and are considered to be a variant of the disease. Although HSTCL is the prototype peripheral T-cell lymphoma expressing the γδ T-cell receptor, ...
The molecular alterations involved in the development of T-cell lymphomas are largely unknown. Expression profiling studies in tumors could be considered as the first step for a molecular diagnosis of cancer, allowing a better subclassification of tumors, identification of undiscovered oncogenic pathways, or prediction of outcome (9, 10, 11, 12 , 29) . Microarray experiments on T-cell malignancies, however, have only been carried out for T-cell acute lymphoblastic leukemias (12) along with some studies on expression profiling using cell lines derived from T-cell malignancies (14, 15, 16) , but expression profiling of primary T-cell lymphomas has only been explored for specific subtypes (13) .. The results reported here show the general expression patterns of T-cell lymphomas. The gene expression of these tumors was compared with normal T-lymphocytes and normal lymph node samples to extract those relevant genes characterizing the tumors. Clustering analysis of tumoral samples easily identify the ...
Diagnosis and chemotherapy of aggressive T-cell lymphoma (costs for program #254369) ✔ University Hospital Frankfurt ✔ Department of Hematology, Oncology, Hemostaseology, Rheumatology and Infectiology ✔ BookingHealth.com
Diagnostics and chemotherapy of aggressive T-cell lymphoma (costs for program #243273) ✔ University Hospital Hamburg-Eppendorf ✔ Department of Pediatric Hematology and Oncology ✔ BookingHealth.com
TY - JOUR. T1 - Single Antibody Detection of T-Cell Receptor αβ Clonality by Flow Cytometry Rapidly Identifies Mature T-Cell Neoplasms and Monotypic Small CD8-Positive Subsets of Uncertain Significance. AU - Shi, Min. AU - Jevremovic, Dragan. AU - Otteson, Gregory E.. AU - Timm, Michael M.. AU - Olteanu, Horatiu. AU - Horna, Pedro. PY - 2019/1/1. Y1 - 2019/1/1. N2 - Background: The diagnosis of T-cell neoplasms is often challenging, due to overlapping features with reactive T-cells and limitations of currently available T-cell clonality assays. The description of an antibody specific for one of two mutually exclusive T-cell receptor (TCR) β-chain constant regions (TRBC1) provide an opportunity to facilitate the detection of clonal TCRαβ T-cells based on TRBC-restriction. Methods: Twenty patients with mature T-cell neoplasms and 44 patients without evidence of T-cell neoplasia were studied. Peripheral blood (51), bone marrow (10), and lymph node (3) specimens were evaluated by 9-color flow ...
CD20-positive T-cell lymphoma is extremely rare and only two cases of CD20-positive NK/T-cell lymphoma with aggressive clinical courses have been described in the literature. We present a case of unus
Looking for small lymphocytic T-cell lymphoma? Find out information about small lymphocytic T-cell lymphoma. a cancer of the tissue of the lymphatic system lymphatic system , network of vessels carrying lymph, or tissue-cleansing fluid, from the tissues into the... Explanation of small lymphocytic T-cell lymphoma
PubMed Central Canada (PMC Canada) provides free access to a stable and permanent online digital archive of full-text, peer-reviewed health and life sciences research publications. It builds on PubMed Central (PMC), the U.S. National Institutes of Health (NIH) free digital archive of biomedical and life sciences journal literature and is a member of the broader PMC International (PMCI) network of e-repositories.
This project is supported by the Canadian Institutes of Health Research (award #111062), Alberta Innovates - Health Solutions, and by The Metabolomics Innovation Centre (TMIC), a nationally-funded research and core facility that supports a wide range of cutting-edge metabolomic studies. TMIC is funded by Genome Alberta, Genome British Columbia, and Genome Canada, a not-for-profit organization that is leading Canadas national genomics strategy with funding from the federal government. Maintenance, support, and commercial licensing is provided by OMx Personal Health Analytics, Inc. Designed by Educe Design & Innovation Inc. ...
Nasal T/NK-cell lymphomas are highly associated with Epstein-Barr virus (EBV). They are more frequent in Asia than in Western countries. In Central and South America there are few studies about nasal T/NK-cell lymphoma and they have shown a strong predominance of this phenotype in Native American descents, supporting the hypothesis of a racial predisposition for the disease. We studied the lymphomas involving midline facial region at a Brazilian institution. T/NK cell lymphomas (16/25) were more frequently found compared to B lymphomas (9 cases, all B large cell). T/NK cell lymphomas involved predominantly the nasal region. Histologically they showed angioinvasion and necrosis. All of them were positive for CD3 and CD56 and showed numerous tumor cells labeled by EBER-1. Although disease was localized in 61% at diagnosis, there was no tendency to cure. The racial distribution of patients with T/NK-cell phenotype was similar to that found in B-cell lymphomas. EBV was more frequently found in ...
We present that L5178Y murine T-cell lymphoma cells can prime naïve murine macrophages (Mϕ) to subsequent LPS stimulation, resulting in antitumor effects in vitro against L5178Y cells. Priming occurred in both cell-type and TLR specific manner, as L5178Y tumor cells (TC), but not naïve splenocytes, primed Mϕ to ligation of TLR4 but not TLR9. L5178Y-primed Mϕ also showed down-regulation of CD40 and CD86 and up-regulation of B7H1, with no changes of TLR4, B7H4, NKG2D and MHC-II expression. Among different TC lines, the priming effect was limited to murine TC of T cell (L5178Y and YAC-1) but not B cell (A20) or nonmyeloid (B16) origin. Human TC lines including Jurkat (T cell), Daudi (B cell), and M21 (melanoma) failed to substantially prime Mϕ. Neither L5178Y-conditioned supernatants nor co-culture of Mϕ and L5178Y TC in transwells resulted in priming, indicating that direct L5178Y TC-Mϕ contact was needed. Furthermore, TLR4-ligation must not precede contact with L5178Y TC in order to ...
A case of a nasal-type NK/T cell lymphoma of the orbit with distant metastases is reported. The orbital lymphoma was angiodestructive with prominent necrosis and frequent... ...
BioAssay record AID 288982 submitted by ChEMBL: Inhibition of P-glycoprotein in MDR mouse T lymphoma cells using rhodamine 123 assessed as ratio of fluorescent uptake relative to untreated control at 1 uM in MDR reversal assay by flow cytometry.
As T-cell receptor sequencing by LymphoTrack is an assay with high sensitivity that can be performed in peripheral blood, the investigators wish to evaluate the ability of this assay to predict which patients are at higher risk of relapse from T-cell lymphoma. Additionally, as more is known about the ability of dynamic monitoring of cfDNA in B-cell lymphomas to predict relapse, the investigators wish to explore the use of this technology in T-cell lymphomas.
Here is a presentation on T-Cell Lymphomas that occurred at the North American Educational Forum on Lymphoma in California in November, 2012. The presenter is Dr. Andrei Shustov of the Fred Hutchinson Cancer Research Center in Seattle. The audience was a patient group, so some of the information is quite basic. However, there is considerable detail regarding the rarity of T-Cell Lymphomas, the difficulty in diagnosing them, as well as treatment philosophy and recent developments, to include
Definition of Adult T-cell lymphoma with photos and pictures, translations, sample usage, and additional links for more information.
TY - JOUR. T1 - Prevalence of HTLV-I-associated T-cell lymphoma. AU - Poiesz, B. J.. AU - Papsidero, L. D.. AU - Ehrlich, G.. AU - Sherman, M.. AU - Dube, S.. AU - Poiesz, M.. AU - Dillon, K.. AU - Ruscetti, F. W.. AU - Slamon, D.. AU - Fang, C.. AU - Williams, A.. AU - Duggan, D.. AU - Glaser, J.. AU - Gottlieb, A.. AU - Goldberg, J.. AU - Ratner, L.. AU - Phillips, P.. AU - Han, T.. AU - Friedman-Kien, A.. AU - Siegal, F.. AU - Rai, K.. AU - Sawitsky, A.. AU - Sheremata, William. AU - Dosik, H.. AU - Cunningham, C.. AU - Montagna, R.. PY - 2001/1/3. Y1 - 2001/1/3. N2 - In order to assess the prevalence rate of HTLV-I-associated T-cell lymphomas and human retrovirus infection in general, approximately 21,000 individuals representing various patient populations, retroviral risk groups, and blood donors were examined for HTLV-I, HTLV-II, HIV-1, or HIV-2 infection using serologic and PCR assays. The prevalence rates among volunteer blood donors were 0.02% and 0% for HTLV and HIV, respectively. ...
TK1 is a T-cell lymphoma cell line originated by E. C. Butcher and I. L. Weissman from a spontaneous thymic lymphoma/leukemia that developed in an AKR/Cum mouse.   Ref
This test includes a charge for application of the first probe set (2 FISH probes) and professional interpretation of results.. Additional charges will be incurred for all reflex probes performed. Analysis charges will be incurred based on the number of cells analyzed per probe set. If no cells are available for analysis, no analysis charges will be incurred.. See Malignant Lymphoma, Guideline for Bone Marrow Staging Studies in Special Instructions.. Depending on the lymphoma subtype suspected, the most appropriate probes to order are listed in Clinical Information.. If the patient is being tracked for known abnormalities, indicate which probes should be used.. Panel includes testing for the following abnormalities using the probes listed:. 14q32.1 rearrangement, TCL1A. -7/7q-/i(7q), D7S486/D7Z1. +8, D8Z2/MYC. This assay detects chromosome abnormalities observed in the blood and bone marrow of patients with T-cell lymphoma. For testing paraffin-embedded tissue samples from patients with T-cell ...
... On-line free medical diagnosis assistant. Ranked list of possible diseases from either several symptoms or a full patient history. A similarity measure between symptoms and diseases is provided.
A recent study examined the varying survival rates among US racial/ethnic patient groups with peripheral T-cell lymphoma subtypes.
The US Food and Drug Administration (FDA) has approved Beleodaq (belinostat) for people with peripheral T-cell lymphoma who did not get better after treatment with other drugs, or whose cancer came back after treatment with other drugs.
CHOP chemotherapy (cyclophosphamide, doxorubicin and vincristine chemotherapy with the steroid prednisolone) is the standard treatment for T-cell lymphoma. However, some people do not respond well to CHOP and alternative treatments are needed.
Sunita D. Nasta, MD, compares the biology of peripheral and cutaneous T-cell lymphomas and offered advice on the optimal therapeutic approaches for either disease with novel agents.
NEW YORK (Reuters Health) - Patients who have undergone prior systemic therapies for cutaneous T-cell lymphoma may respond well to treatment with romidepsin, a potent inhibitor of histone deacetylases, according to the results of a multicenter, open-label phase II study. Dr. Sean Whittaker of St. Thomas Hospital, London, UK and colleagues...
Immunogen was an epitope that maps to a region between residues 1550 and the C-terminus (residue 1591) of human T-cell lymphoma invasion and metastasis 1 using the numbering given in entry NP_003244.1 (GeneID 7074) (ZFIN Staff ...
T-cells are very important members of the immune system and their three main roles are to help other parts of the immune system to do their job, to directly kill infections/cancers in the body and also to regulate the immune system so as to not attack itself. Sadly, T-cells can be develop cancer themselves and they can be difficult to treat. CPI-818 is a new tablet treatment which targets the internal machinery of the cancerous T-cell. In Western Australia the first patients in the world are being treated with this medicine and people who are eligible for this clinical trial are those with T-cell lymphoma which has persisted or come back after two different combinations of chemotherapy". ...
Maybaum, J; Ullman, B; Mandel, H G.; Day, J L.; and Sadee, D W., "In mouse t-lymphoma (s-49) cells." (1980). Subject Strain Bibliography 1980. 581 ...
Purpose: This study will evaluate the safety of CHOP plus Alemtuzumab in patients with T/NK cell lymphomas and CD-20 negative large B-cell lymphomas who
It is a type I transmembrane protein present on activated T cells, activated B cells, some thymocytes, myeloid precursors, and oligodendrocytes. Though IL2RA has been used as a marker to identify CD4+FoxP3+ regulatory T cells in mice, it has been found that a large proportion of resting memory T cells constitutively express IL2RA in humans.[3] IL2RA is expressed in most B-cell neoplasms, some acute nonlymphocytic leukemias, neuroblastomas, mastocytosis and tumor infiltrating lymphocytes. It functions as the receptor for HTLV-1 and is consequently expressed on neoplastic cells in adult T cell lymphoma/leukemia. Its soluble form, called sIL-2R may be elevated in these diseases and is occasionally used to track disease progression. ...
... Classification & external resources MeSH D016399 T-cell lymphoma describes several different types of Non-Hodgkin lymphoma which
A novel full-length cDNA was isolated from a murine T-cell lymphoma library that has an open reading frame encoding 381 amino acids. The predicted protein (termed SLY) contains a Src homology 3 domain and a sterile alpha motif, suggesting that it functions as a signaling adaptor protein in lymphocyt …
T cell lymphoma is a heterogenic malignancy with poor outcome. Five-year PFS and OS of the patients recieved classic CHOP regimen(cyclophosphamide,vincr
... , Authors: Antonio Cuneo, Francesco Cavazzini, Gian Matteo Rigolin. Published in: Atlas Genet Cytogenet Oncol Haematol.
People have been cured of cancer, using Protocel, in so many varied types of cancers and stages of cancer and it seems that no 2 people have exactly the same reaction to Protocel, in terms of lysing and so on. When I began my search for a new alternative treatment (the previous alternatives I tried may have held it at bay somewhat but I was at Stage 4 with metastesis to several places in Dec. of 09) I was hoping to read about someone exactly like me who had been cured. Well, although there are many women with breast cancer, no 2 of us has Exactly the same cancer with the same number of cancer cells with the same immune system and so many other variables. Instead, I found that the same basic rules (about taking Protocel) apply and its very comforting to have a community of people, here on the forum, on the same healing journey who have been through or are going through or are related to someone going through what I am going through. That support goes a long way towards helping a person have a ...
If you use this products in your scientific publication, it should be cited in the publication as: Creative Bioarray cat no. If your paper has been published, please click here to submit the Pub Med ID of your paper to get a coupon. ...
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) reported encouraging data from its ongoing Phase 1 study of IPI-145, its oral inhibitor of phosphoinosit
Age and HIV status independently altered the immune system, but we found no conclusive evidence that HIV infection and advancing age synergistically result in accelerated changes in age-associated T-cell markers among virally suppressed individuals.
14.11.2017 - A unique approach to targeting the abnormal T-cells that cause T-cell lymphomas could offer hope to patients with the aggressive and difficult-to-treat family of cancers, finds a study involving researchers from Cardiff University.
Expression of NT5C2 (cN-II, GMP, NT5B, PNT5, SPG65) in nasopharynx tissue. Antibody staining with HPA003751 in immunohistochemistry.
Enteropathy-associated T-cell lymphoma (EATL), also enteropathy-type T-cell lymphoma (ETTL), is a type of T-cell lymphoma that affects the small intestine. It is the most common primary gastrointestinal T-cell lymphoma, arising from the T cells that are found between the cells that line the small intestinal (brush border cells or small intestinal epithelial cells). These cancerous T-cells are a possible consequence of refractory cases of coeliac disease or in chronic, untreated cases in genetically susceptible individuals. EATL can be classified as an extranodal peripheral T cell lymphoma, a category it shares with hepatosplenic T cell lymphoma and panniculitic T cell lymphoma. It can be further classified in type I and II EATL. Enteropathy associated T-cell lymphoma (EATL) is environmentally induced as a result of the consumption of Triticeae glutens (e.g. wheat gluten). In gluten-sensitive individuals with EATL, 68% are homozygotes of the DQB1*02 subtype at the HLA-DQB1 locus. (See Coeliac ...
The angiogenic microenvironment has been known to be a component of angioimmunoblastic T-cell lymphoma since its initial characterization. We have shown that angioimmunoblastic T-cell lymphoma endothelial cells produce vascular endothelial growth factor-A (VEGFA), and participate in lymphoma progression. In squamous cell carcinoma, endothelial BCL2 expression induces a crosstalk with tumor cells through VEGFA, a major mediator of tumoral angiogenesis. In the present study, we analyzed BCL2 and VEGFA in 30 angioimmunoblastic T-cell lymphomas, using triple immunofluorescence to identify protein coexpression in well-characterized lymphoma cells and microenvironment neoangiogenic endothelial cells. Using quantitative real-time PCR, we assessed mRNA expression levels in laser-microdissected endothelial and lymphoma cells. In lymphoma cells, as in endothelial cells, BCL2 and VEGFA proteins were coexpressed. BCL2 was expressed only in neoangiogenic CD34(+)CD105(+) endothelial cells. In laser-microdissected
Angioimmunoblastic T-cell lymphoma (AITL) is an aggressive subtype of peripheral T-cell lymphoma (PTCL) that accounts for approximately 20% of all T-cell lymphomas. Although recurrent mutations in TET2, IDH2, and DNMT3A that are common in other hematologic malignancies have been identified in AITL, the molecular mechanisms that specifically promote AITL development are unknown. Sakata-Yanagimoto and colleagues performed whole-exome sequencing on 6 AITL samples and identified a recurrent RHOA G17V mutation in 3 AITL samples. Targeted RHOA sequencing in an extended AITL cohort identified RHOA G17V mutations in 49 of 72 (68%) AITLs. Similarly, Palomero and colleagues analyzed the exomes of 12 PTCL cases and identified recurrent RHOA G17V mutations in 22 of 35 (67%) AITLs. No RHOA G17V mutations were identified in other hematologic malignancies other than in a subset of PTCL not otherwise specified that shared AITL features, suggesting that somatic RHOA mutations are a specific feature of AITL. Of ...
Angioimmunoblastic T-cell lymphoma (AITL, sometimes misspelled AILT) (formerly known as "angioimmunoblastic lymphadenopathy with dysproteinemia") is a mature T-cell lymphoma of blood or lymph vessel immunoblasts characterized by a polymorphous lymph node infiltrate showing a marked increase in follicular dendritic cells (FDCs) and high endothelial venules (HEVs) and systemic involvement. Patients with this disease usually present at an advanced stage and show systemic involvement. The clinical findings typically include a pruritic skin rash and possibly edema, ascites, pleural effusions, and arthritis. Due to the systemic nature of this disease, neoplastic cells can be found in lymph nodes, liver, spleen, skin, and bone marrow. This disease was originally thought to be a premalignant condition, termed angioimmunoblastic lymphadenopathy, and this atypical reactive lymphadenopathy carried a risk for transformation into a lymphoma. Currently, it is postulated that the originating cell for this ...
TY - JOUR. T1 - Outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas. AU - Lee, Hoon K.. AU - Wilder, Richard B.. AU - Jones, Dan. AU - Ha, Chul S. AU - Pro, Barbara. AU - Rodriguez, Maria A.. AU - Romaguera, Jorge E.. AU - Cabanillas, Fernando. AU - Rodriguez, Jose. AU - Cox, James D.. PY - 2002. Y1 - 2002. N2 - There is little information in the literature on outcomes using doxorubicin-based chemotherapy with or without radiotherapy for early-stage peripheral T-cell lymphomas. The purpose of this study was to analyze The University of Texas M.D. Anderson Cancer Center results in such patients. From 1985 to 1998, 39 patients with Stage I or II World Health Organization classification anaplastic large cell lymphoma (ALCL; n = 20), peripheral T-cell lymphoma, unspecified (PTCLu; n = 11), or nasal-type NK/T-cell lymphoma (NKTCL; n = 8) were treated using doxorubicin-based chemotherapy (median, 6 cycles) with (n = 24) or without (n = ...
Adult Acute Lymphoblastic Leukemia in Remission Adult B Acute Lymphoblastic Leukemia Adult Hepatocellular Carcinoma Adult Nasal Type Extranodal NK/T-Cell Lymphoma Adult Solid Neoplasm Adult T Acute Lymphoblastic Leukemia Advanced Adult Hepatocellular Carcinoma Anaplastic Large Cell Lymphoma Angioimmunoblastic T-Cell Lymphoma Chronic Lymphocytic Leukemia Cutaneous B-Cell Non-Hodgkin Lymphoma Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue Hepatosplenic T-Cell Lymphoma Intraocular Lymphoma Localized Non-Resectable Adult Liver Carcinoma Localized Resectable Adult Liver Carcinoma Lymphomatous Involvement of Non-Cutaneous Extranodal Site Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma Nodal Marginal Zone Lymphoma Progressive Hairy Cell Leukemia Initial Treatment Recurrent Adult Acute Lymphoblastic Leukemia Recurrent Adult Burkitt Lymphoma Recurrent Adult Diffuse Large Cell Lymphoma Recurrent Adult Diffuse Mixed Cell Lymphoma Recurrent Adult Diffuse Small Cleaved Cell Lymphoma ...
Thank you very much for your kind words. T-Cell Lymphomas are so rare, so aggressive, and so difficult to treat, that I try to reposnd quickly when I see another case. My doctor is Dr. Andrei Shustov at Seattle Cancer Care Alliance, which is the treatment arm of Fred Hutchinson. In conjunction with his peers, he formulated the regimen that, against odds, placed me initially in full response. Not completely unexpected was that some cells survived, demonstrating that the variety I had was highly resistant to all chemotherapy. He also researched and offered me the clinical trial in which I yet participate in the long-term study. Your doctor could certainly consult with him regarding your husbands options as, with all T-Cell Lymphomas, a second opinion on both diagnosis and treatment is a very good idea. I rather doubt that Health Canada would pay for any portion of US treatment. Are there any clinical trials for AITL (or any T-Cell Lymphoma) in Canada? It is good to have a plan B in reserve, as ...
Thank you very much for your kind words. T-Cell Lymphomas are so rare, so aggressive, and so difficult to treat, that I try to reposnd quickly when I see another case. My doctor is Dr. Andrei Shustov at Seattle Cancer Care Alliance, which is the treatment arm of Fred Hutchinson. In conjunction with his peers, he formulated the regimen that, against odds, placed me initially in full response. Not completely unexpected was that some cells survived, demonstrating that the variety I had was highly resistant to all chemotherapy. He also researched and offered me the clinical trial in which I yet participate in the long-term study. Your doctor could certainly consult with him regarding your husbands options as, with all T-Cell Lymphomas, a second opinion on both diagnosis and treatment is a very good idea. I rather doubt that Health Canada would pay for any portion of US treatment. Are there any clinical trials for AITL (or any T-Cell Lymphoma) in Canada? It is good to have a plan B in reserve, as ...
Dr. Assanie-Shivjis Ph.D thesis work was carried out under the supervision of Dr. Shahid Pervez, Department of Pathology and Microbiology, Aga Khan University Hospital, Karachi, Pakistan. She studied immunological aspects of 99 T-cell Non-Hodgkins Lymphoma (T-NHL) cases from Pakistan; correlating the immunohistochemical aspects of the disease with the molecular level by studying T-cell receptor (TCR) and Immunoglobulin Heavy (IgH) chain gene rearrangements and their association with Epstein-Barr virus (EBV) and Human T-cell Lymphotropic Virus Type-I (HTLV-I) infections.. As a post-doctoral fellow under the supervision of Dr. Juergen Vielkind, in the Department of Cancer Endocrinology at BC Cancer Research Centre, Vancouver, B.C., Canada, Dr. Assanie-Shivji identified the role of growth differentiation factor 15 (gdf15) in the development of the normal prostate during early stages of embryogenesis and in prostate cancer in a transgenic mouse model, 12T-7s.. After completing her post-doctoral ...